TrialClinical genitourinary cancer2013

Phase II study of satraplatin and prednisone in patients with metastatic castration-resistant prostate cancer: a pharmacogenetic assessment of outcome and toxicity.

William D Figg et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.